DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Tasquinimod is an investigational drug.
There have been 9 clinical trials for Tasquinimod. The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2011.
The most common disease conditions in clinical trials are Prostatic Neoplasms, Carcinoma, and Stomach Neoplasms. The leading clinical trial sponsors are Active Biotech AB, Ipsen, and Sidney Kimmel Comprehensive Cancer Center.
There are eleven US patents protecting this investigational drug and one hundred and one international patents.
Recent Clinical Trials for Tasquinimod
|A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer||Sidney Kimmel Comprehensive Cancer Center||Phase 1|
|Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer||Active Biotech AB||Phase 2|
|Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer||National Cancer Institute (NCI)||Phase 2|
Top disease conditions for Tasquinimod
Top clinical trial sponsors for Tasquinimod
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Tasquinimod||See Pricing||Quinoline carboxamides for use in the treatment of leukemia||ACTIVE BIOTECH AB (Lund, SE)||See Pricing|
|Tasquinimod||See Pricing||Quinoline carboxamides for use in the treatment of multiple myeloma||Active Biotech AB (Lund, SE)||See Pricing|
|Tasquinimod||See Pricing||Quinoline derivatives||Active Biotech AB (Lund, SE)||See Pricing|
|Tasquinimod||See Pricing||Drugs for the treatment of malignant tumors||Active Biotech AB (Lund, SE)||See Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|